Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice

Vaccine

Volumn 30, Issue 23, 2012, Pages 3463-3469

  Zhou, Chang ^a   Zhou, Leilei ^a   Chen, Ying Hua ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

Immunity; Influenza virus; M2 epitope; Protection

Indexed keywords

EPITOPE; GLUTATHIONE TRANSFERASE; INFLUENZA VACCINE; PROTEIN M2E; PROTEIN SFM2E; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS PROTEIN;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINATION; VIRAL MATRIX PROTEINS;

EID: 84859824268     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.021     Document Type: Article

References (35)

1. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360(25):2605-2615.
2. Gerhard W., Mozdzanowska K., Zharikova D. Prospects for universal influenza virus vaccine. Emerg Infect Dis 2006, 12(4):569-574.
3. Ebrahimi S.M., Tebianian M. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes 2010, 42(1):1-8.
4. Feng J., Zhang M., Mozdzanowska K., Zharikova D., Hoff H., Wunner W., et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 2006, 3:102.
5. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5(10):1157-1163.
6. De Filette M., Min Jou W., Birkett A., Lyons K., Schultz B., Tonkyro A., et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005, 337(1):149-161.
7. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26(2):201-214.
8. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22(23-24):2993-3003.
9. Bessa J., Schmitz N., Hinton H.J., Schwarz K., Jegerlehner A., Bachmann M.F. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 2008, 38(1):114-126.
10. Liu W., Peng Z., Liu Z., Lu Y., Ding J., Chen Y.H. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 2004, 23(3):366-371.
11. Liu W., Zou P., Ding J., Lu Y., Chen Y.H. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect 2005, 7(2):171-177.
12. Liu W., Zou P., Chen Y.H. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett 2004, 93(2-3):131-136.
13. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325(5937):197-201.
14. Soboleski M.R., Gabbard J.D., Price G.E., Misplon J.A., Lo C.Y., Perez D.R., et al. Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS One 2011, 6(7):e21937.
15. Shim B.S., Choi Y.K., Yun C.H., Lee E.G., Jeon Y.S., Park S.M., et al. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS One 2011, 6(11):e27953.
16. McLachlan J.B., Shelburne C.P., Hart J.P., Pizzo S.V., Goyal R., Brooking-Dixon R., et al. Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med 2008, 14(5):536-541.
17. Meng S., Liu Z., Xu L., Li L., Mei S., Bao L., et al. Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice. PLoS One 2011, 6(5):e19863.
18. Liu Z., Chen Y.H. Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy. J Immunol Methods 2004, 285(1):93-97.
19. Wu F., Huang J.H., Yuan X.Y., Huang W.S., Chen Y.H. Characterization of immunity induced by M2e of influenza virus. Vaccine 2007, 25(52):8868-8873.
20. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13(3):426-435.
21. Lo C.Y., Wu Z., Misplon J.A., Price G.E., Pappas C., Kong W.P., et al. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 2008, 26(17):2062-2072.
22. Heinen P.P., Rijsewijk F.A., de Boer-Luijtze E.A., Bianchi A.T. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 2002, 83(Pt. 8):1851-1859.
23. Zhao G., Lin Y., Du L., Guan J., Sun S., Sui H., et al. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 2010, 7:9.
24. Sui Z., Chen Q., Wu R., Zhang H., Zheng M., Wang H., et al. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Arch Virol 2010, 155(4):535-544.
25. Misplon J.A., Lo C.Y., Gabbard J.D., Tompkins S.M., Epstein S.L. Genetic control of immune responses to influenza A matrix 2 protein (M2). Vaccine 2010, 28(36):5817-5827.
26. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172(9):5598-5605.
27. El Bakkouri K., Descamps F., De Filette M., Smet A., Festjens E., Birkett A., et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011, 186(2):1022-1031.
28. Song J.M., Van Rooijen N., Bozja J., Compans R.W., Kang S.M. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci USA 2010, 108(2):757-761.
29. Lu L., Zhu Y., Diao J., Wang Z., Chen Y.H. V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory CD8+ T cells. Vaccine 2008, 26(6):845-852.
30. McGowen A.L., Hale L.P., Shelburne C.P., Abraham S.N., Staats H.F. The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine 2009, 27(27):3544-3552.
31. Chen Y.H., Xiao Y., Yu T., Dierich M.P. Epitope vaccine: a new strategy against HIV-1. Immunol Today 1999, 20(12):588-589.
32. Liu Z., Xiao Y., Chen Y.H. Epitope-vaccine strategy against HIV-1: today and tomorrow. Immunobiology 2003, 208(4):423-428.
33. Wang J., Xu L., Tong P., Chen Y.H. Mucosal antibodies induced by tandem repeat of 2F5 epitope block transcytosis of HIV-1. Vaccine 2011, 29(47):8542-8548.
34. Xiao Y., Zhao Y., Lu Y., Chen Y.H. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody. Immunol Invest 2000, 29(1):41-50.
35. Qi Y., Zhang B.Q., Shen Z., Chen Y.H. Candidate vaccine focused on a classical swine fever virus epitope induced antibodies with neutralizing activity. Viral Immunol 2009, 22(3):205-213.